Acs Fall 2024 Vvd-130037. Explore acs fall 2024 agenda: Vividion has already disclosed work on covalent keap1 inhibitors, but at the recent acs fall 2024 meeting, the structure and discovery story of their clinical oral covalent.

Technical sessions, networking, career development & more. The bms team sought to develop a celmod® for ck1α degradation.